Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Aprin Sama Pharmed
Iran
- Ownership
- Private
- Development stage
- Other
01
Overview
Tilmanocept, a peptide-based radiopharmaceutical, completed preclinical studies and entered clinical trials in Iran, enabling affordable, accurate lymphatic mapping for cancer diagnosis and potentially improving lives for 90% of cancer patients in the region. Aprin Sama Pharmed is responsible for the manufacturing of peptide APIs and custom synthesis services
- Therapeutic areas
- Oncology
- Modalities
- PeptideNanoparticleRadiopharmaceutical
- Industry
- Biotech
Beyond the preview
Go deeper on Aprin Sama Pharmed.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aprin Sama Pharmed.